Dendreon Prostate Vaccine Boosts Survival

Dendreon's controversial Provenge cancer vaccine may get another chance two years after the FDA rejected it. The drugmaker's stock soared on the news

Dendreon Corp. (DNDN) jolted the cancer community, and the stock market, on Apr. 14 with an announcement that a medical trial has shown that its experimental Provenge vaccine for prostate cancer can keep men alive longer than standard treatments. "The results were unambiguous," Dendreon CEO Mitchell Gold told BusinessWeek. The news raised the possibility that Provenge might become the first cancer vaccine approved for use in the U.S.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.